Koonenberry (ASX:KNB) is aiming to uncover potential repetitions of the broad, high-grade mineralisation already intersected ...
After discussions with the FDA, Nuvation disclosed that it has “decided not to pursue a head-to-head randomized study of safusidenib against vorasidenib to support approval in non-enhancing grade 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback